Navigation Links
Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
Date:2/14/2012

ROCKVILLE, Md., Feb. 14, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced today that it has closed on its previously announced registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share, and 5,200,000 warrants each with an exercise price of $1.02 per share and exercisable starting six months from the issuance date for a term of five years. The company received aggregate gross proceeds of $5,200,000, which will be used for general corporate purposes, including ongoing U.S. clinical trials.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

T.R. Winston & Company, LLC acted as the exclusive placement agent for the offering.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and pate
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
4. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
5. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
6. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
7. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
8. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
9. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
10. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
11. Neuralstem Completes $5.25 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... TRIANGLE PARK, N.C. , July 14, 2014 ... focused on cloud-based drug design and development, announced ... development program. The company has been granted supercomputing ... of multiple parasitic targets.  Through ... the Argonne Leadership Computing Facility (ALCF), researchers at ...
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... 14, 2014 Minerva Neurosciences (NASDAQ: ... therapies to treat neuropsychiatric diseases and disorders, today announced ... vice president of finance and chief accounting officer, effective ... senior executive with more than 20 years of experience ... science companies. His background includes the management of compliance ...
(Date:7/14/2014)... San Mateo, CA (PRWEB) July 14, 2014 ... groundbreaking CONNECT patient registry platform, announced that ... Becker muscular dystrophies; the Phelan-McDermid Syndrome International ... primary Nephrotic Syndrome—have been awarded contracts by ... part of the creation of a new ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... Inc., the,leading developer of stents designed for the ... has closed a $14 million Series,C round of ... Venture,Partners joined with Spray Venture Partners in the ... RiverVest have been appointed to the Tryton,Board of ...
... blood pressure of elderly patients could cut their total,mortality ... by a third,according to a new study presented today ... simultaneously in the New England,Journal of Medicine., LONDON, ... Elderly Trial (HYVET), which is co-ordinated by scientists from,Imperial ...
... discover and develop ... SAN FRANCISCO, March 31 The Immune Tolerance Institute,Inc. ... a Center for Critical Path Immunology to investigate the role ... be managed by,ITI and located initially at Beckman Coulter,s Cellular ...
Cached Biology Technology:Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 2Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 4The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 2The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 3
(Date:7/14/2014)... German . , ... development. One classical example is the sequential and rhythmic ... that has been linked to the ticking of an ... now, this patterning process was thought to be determined ... periodically trigger new segment formation. However, this week in ...
(Date:7/14/2014)... MedNet Solutions , a global ... management systems, is pleased to announce that ... on software-as-a-service (SaaS) and Internet-based businesses, has made ... funding, representing the first major outside financing in ... the ongoing growth and development of both MedNet ...
(Date:7/14/2014)... 14, 2014 Research and Markets has ... 2014: Applications for Microfluidic Technologies" report to their offering. ... testing based on microfluidic technology is expected to grow sharply, ... CAGR 2014 - 2019 of 23%. Major diagnostics companies (Alere, ... etc.) have realized the potential of rapid molecular diagnostic testing. ...
Breaking Biology News(10 mins):Timing is not only ticking 2Timing is not only ticking 3Arrowroot Capital Invests $4 Million In MedNet Solutions 2Arrowroot Capital Invests $4 Million In MedNet Solutions 3Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 2Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 3
... New evidence suggests that the risk of HIV transmission ... According to a study published in the April ... available online, early infection accounted for nearly half of ... province of Quebec, Canada. , Bluma Brenner, PhD, and ...
... Turn up the white noise, says a team of ... the benefits of noise. Their findings could lead to ... an assistant professor of computer science, Joseph Martin, a ... of biology, are working together to explain the biological ...
... no two brains are alike, they can display a ... sensory input. Scientists at the Max Planck Institute for ... mathematical method to design networks from neural cells which ... their method will assist them in getting closer to ...
Cached Biology News:Risk of HIV transmission highest early in infection 2Noise echoes in cell communications 22 brains -- 1 thought 22 brains -- 1 thought 3
...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
... Beagle serum is collected from fasted Beagle canines ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
... cDNA Purification Kit is designed to purify double-stranded ... cDNA synthesis and PCR. The process is simple ... to 3 g can be efficiently purified and ... 1) DNA is bound to the Microfilter Cartridge ...
Biology Products: